Access, SpePharm Announce Licensing of MuGard for Europe

Dutch drug company SpePharm and Access Pharmaceuticals have signed a definitive licensing agreement under which SpePharm will market Access’s product MuGard in Europe, the companies announced.

MuGard is Access’ product for the management of oral mucositis, a side effect of many anticancer treatments.

MuGard has received marketing allowance in the U.S. from the FDA.

SpePharm said it will be responsible for marketing MuGard throughout the EU as well as Switzerland, Norway and Iceland, as well as manufacturing and obtaining the necessary regulatory approvals for the product.